Bird & Bird Advises Orphalan on Acquisition of Orphelia Pharma

Bird & Bird advised Orphalan, and Jones Day advised Orphelia Pharma in connection with Orphalan's acquisition of Orphelia Pharma. The transaction concerns the acquisition by Orphalan, a laboratory specialising in the development and commercialisation of orphan drugs, of Orphelia Pharma, a French company focused on rare and severe paediatric diseases in neurology and oncology. Orphalan, founded in 2011 from a collaboration between the General Agency for Health Products (AGEPS) and Lariboisière Hospital, commercialises Cuprior®, a treatment for Wilson's disease that is approved and authorised in 38 countries and sold in 28 markets. The group pursues a mission to reduce diagnostic delays and improve access to innovative treatments for patients with rare diseases. Based in Paris and Lyon, Orphelia Pharma has a medicine authorised in Europe since 2018, Kigabeq®, a paediatric antiepileptic. The company is also developing Kizfiko®/Kimozo®, which benefited from early access in France for the treatment of a form of high‑risk neuroblastoma in children between 2022 and 2025. Following the transaction, Orphelia Pharma is intended to be fully integrated within Orphalan. The acquisition will enable the combined group to build a unique platform that couples scientific expertise with global commercialisation capabilities, accelerating innovation and improving access to treatments worldwide. For Orphalan, the strategic transaction represents an opportunity to strengthen its orphan-drug portfolio and expand its expertise in rare paediatric diseases, consolidating its position in the development and commercialisation of treatments for patients with rare conditions. Bird & Bird represented client(s) Orphalan with a team composed by: partner Olivier Peronnau and associate Céline Sol. Jones Day represented client(s) Orphelia Pharma with a team composed by: Geoffroy Pineau-Valencienne and Guillaume Bonhoure.

Bird & Bird Advises Orphalan on Acquisition of Orphelia Pharma

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads